S&P 500   4,356.45 (-1.22%)
DOW   34,297.73 (-0.19%)
QQQ   345.11 (-2.32%)
AAPL   159.78 (-1.14%)
MSFT   288.49 (-2.66%)
FB   300.15 (-2.77%)
GOOGL   2,538.70 (-2.96%)
AMZN   2,799.72 (-3.15%)
TSLA   918.40 (-1.25%)
NVDA   223.24 (-4.48%)
BABA   119.14 (-1.02%)
NIO   23.79 (-4.34%)
AMD   111.13 (-4.63%)
CGC   7.36 (-0.54%)
MU   80.72 (-2.69%)
GE   91.11 (-5.98%)
T   26.48 (+0.53%)
F   19.98 (-2.01%)
DIS   136.51 (-0.69%)
AMC   16.02 (-3.73%)
PFE   52.54 (+1.94%)
ACB   4.21 (-2.55%)
BA   204.10 (-0.05%)
S&P 500   4,356.45 (-1.22%)
DOW   34,297.73 (-0.19%)
QQQ   345.11 (-2.32%)
AAPL   159.78 (-1.14%)
MSFT   288.49 (-2.66%)
FB   300.15 (-2.77%)
GOOGL   2,538.70 (-2.96%)
AMZN   2,799.72 (-3.15%)
TSLA   918.40 (-1.25%)
NVDA   223.24 (-4.48%)
BABA   119.14 (-1.02%)
NIO   23.79 (-4.34%)
AMD   111.13 (-4.63%)
CGC   7.36 (-0.54%)
MU   80.72 (-2.69%)
GE   91.11 (-5.98%)
T   26.48 (+0.53%)
F   19.98 (-2.01%)
DIS   136.51 (-0.69%)
AMC   16.02 (-3.73%)
PFE   52.54 (+1.94%)
ACB   4.21 (-2.55%)
BA   204.10 (-0.05%)
S&P 500   4,356.45 (-1.22%)
DOW   34,297.73 (-0.19%)
QQQ   345.11 (-2.32%)
AAPL   159.78 (-1.14%)
MSFT   288.49 (-2.66%)
FB   300.15 (-2.77%)
GOOGL   2,538.70 (-2.96%)
AMZN   2,799.72 (-3.15%)
TSLA   918.40 (-1.25%)
NVDA   223.24 (-4.48%)
BABA   119.14 (-1.02%)
NIO   23.79 (-4.34%)
AMD   111.13 (-4.63%)
CGC   7.36 (-0.54%)
MU   80.72 (-2.69%)
GE   91.11 (-5.98%)
T   26.48 (+0.53%)
F   19.98 (-2.01%)
DIS   136.51 (-0.69%)
AMC   16.02 (-3.73%)
PFE   52.54 (+1.94%)
ACB   4.21 (-2.55%)
BA   204.10 (-0.05%)
S&P 500   4,356.45 (-1.22%)
DOW   34,297.73 (-0.19%)
QQQ   345.11 (-2.32%)
AAPL   159.78 (-1.14%)
MSFT   288.49 (-2.66%)
FB   300.15 (-2.77%)
GOOGL   2,538.70 (-2.96%)
AMZN   2,799.72 (-3.15%)
TSLA   918.40 (-1.25%)
NVDA   223.24 (-4.48%)
BABA   119.14 (-1.02%)
NIO   23.79 (-4.34%)
AMD   111.13 (-4.63%)
CGC   7.36 (-0.54%)
MU   80.72 (-2.69%)
GE   91.11 (-5.98%)
T   26.48 (+0.53%)
F   19.98 (-2.01%)
DIS   136.51 (-0.69%)
AMC   16.02 (-3.73%)
PFE   52.54 (+1.94%)
ACB   4.21 (-2.55%)
BA   204.10 (-0.05%)
NASDAQ:SGMO

Sangamo Therapeutics Stock Competitors

$5.97
+0.04 (+0.67%)
(As of 01/25/2022 12:00 AM ET)
Add
Compare
Today's Range
$5.67
$6.07
50-Day Range
$5.68
$9.80
52-Week Range
$5.32
$15.45
Volume
1.26 million shs
Average Volume
1.66 million shs
Market Capitalization
$869.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.5

Sangamo Therapeutics (NASDAQ:SGMO) Vs. AMGN, GILD, REGN, VRTX, BIIB, SGEN, INCY, ALNY, BMRN, and EXAS

Should you be buying Sangamo Therapeutics stock or one of its competitors? The main competitors of Sangamo Therapeutics include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), and Exact Sciences (EXAS). These companies are all part of the "biotechnology" industry.

Sangamo Therapeutics vs.

Gilead Sciences (NASDAQ:GILD) and Sangamo Therapeutics (NASDAQ:SGMO) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation, dividends and community ranking.

Gilead Sciences has higher revenue and earnings than Sangamo Therapeutics. Sangamo Therapeutics is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gilead Sciences$24.69 billion3.50$123 million$5.8611.75
Sangamo Therapeutics$118.19 million7.36-$121 million-$1.27-4.70

Gilead Sciences has a beta of 0.34, meaning that its stock price is 66% less volatile than the S&P 500. Comparatively, Sangamo Therapeutics has a beta of 1.5, meaning that its stock price is 50% more volatile than the S&P 500.

Gilead Sciences has a net margin of 26.91% compared to Sangamo Therapeutics' net margin of -167.16%. Gilead Sciences' return on equity of 56.59% beat Sangamo Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Gilead Sciences 26.91% 56.59% 16.36%
Sangamo Therapeutics -167.16% -39.90% -21.19%

Gilead Sciences currently has a consensus target price of $79.18, indicating a potential upside of 15.02%. Sangamo Therapeutics has a consensus target price of $18.40, indicating a potential upside of 208.21%. Given Sangamo Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Sangamo Therapeutics is more favorable than Gilead Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gilead Sciences
0 Sell rating(s)
6 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.57
Sangamo Therapeutics
0 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.60

Gilead Sciences received 1985 more outperform votes than Sangamo Therapeutics when rated by MarketBeat users. Likewise, 79.18% of users gave Gilead Sciences an outperform vote while only 66.20% of users gave Sangamo Therapeutics an outperform vote.

CompanyUnderperformOutperform
Gilead SciencesOutperform Votes
2408
79.18%
Underperform Votes
633
20.82%
Sangamo TherapeuticsOutperform Votes
423
66.20%
Underperform Votes
216
33.80%

In the previous week, Gilead Sciences had 22 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 24 mentions for Gilead Sciences and 2 mentions for Sangamo Therapeutics. Gilead Sciences' average media sentiment score of 0.02 beat Sangamo Therapeutics' score of -0.21 indicating that Gilead Sciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Gilead Sciences
3 Very Positive mention(s)
3 Positive mention(s)
8 Neutral mention(s)
6 Negative mention(s)
1 Very Negative mention(s)
Neutral
Sangamo Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

78.7% of Gilead Sciences shares are owned by institutional investors. Comparatively, 52.0% of Sangamo Therapeutics shares are owned by institutional investors. 0.1% of Gilead Sciences shares are owned by insiders. Comparatively, 2.1% of Sangamo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Gilead Sciences beats Sangamo Therapeutics on 13 of the 18 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SGMO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment >-1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

Sangamo Therapeutics (NASDAQ:SGMO) vs. Its Competitors

TypeSangamo TherapeuticsBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$869.68M$2.84B$4.53B$6.78B
Dividend YieldN/A2.10%2.07%2.96%
P/E Ratio-4.707.6216.1518.41
Price / Sales7.362,450.665,656.93229.83
Price / CashN/A65.9161.0368.47
Price / Book1.704.217.428.77
Net Income-$121M$2.52M$98.30M$156.36M
7 Day Performance0.67%-3.95%-4.45%-4.46%
1 Month Performance-30.42%-20.87%-14.90%-11.45%
1 Year Performance-60.33%-48.45%-22.42%-9.27%

Sangamo Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AMGN
Amgen
2.6991 of 5 stars
$225.04
+0.5%
$232.24
+3.2%
-10.8%$126.76B$25.42B23.1824,300Upcoming Earnings
Analyst Revision
GILD
Gilead Sciences
3.3238 of 5 stars
$68.84
+0.4%
$79.18
+15.0%
+2.4%$86.35B$24.69B11.7513,600Upcoming Earnings
Analyst Revision
REGN
Regeneron Pharmaceuticals
2.6092 of 5 stars
$603.19
+3.0%
$729.53
+20.9%
+15.6%$64.87B$8.50B9.639,123
VRTX
Vertex Pharmaceuticals
2.1556 of 5 stars
$227.11
+1.1%
$255.47
+12.5%
-3.3%$57.74B$6.21B27.263,400Upcoming Earnings
Analyst Revision
BIIB
Biogen
2.1681 of 5 stars
$222.31
+1.1%
$307.42
+38.3%
-16.6%$32.66B$13.44B21.759,100Analyst Report
Analyst Revision
SGEN
Seagen
2.692 of 5 stars
$125.10
+3.6%
$182.82
+46.1%
-29.1%$22.88B$2.18B-67.622,092Gap Down
INCY
Incyte
2.9083 of 5 stars
$74.15
+1.6%
$89.60
+20.8%
-23.0%$16.38B$2.67B30.771,773
ALNY
Alnylam Pharmaceuticals
2.5 of 5 stars
$130.94
+4.3%
$214.63
+63.9%
-20.8%$15.66B$492.85M-18.361,453
BMRN
BioMarin Pharmaceutical
2.7536 of 5 stars
$84.86
+1.6%
$112.57
+32.7%
-2.0%$15.58B$1.86B1,060.753,059
EXAS
Exact Sciences
2.3909 of 5 stars
$69.18
+7.9%
$136.09
+96.7%
-50.2%$11.92B$1.49B-13.925,000Gap Down
RGEN
Repligen
2.3831 of 5 stars
$185.40
+2.4%
$316.86
+70.9%
-13.5%$10.25B$366.26M88.291,128Gap Down
UTHR
United Therapeutics
2.3415 of 5 stars
$199.72
+1.2%
$232.67
+16.5%
+20.5%$8.99B$1.48B20.24950
NBIX
Neurocrine Biosciences
2.7279 of 5 stars
$75.93
+0.1%
$114.79
+51.2%
-35.1%$7.20B$1.05B16.61845Analyst Revision
NVAX
Novavax
2.1298 of 5 stars
$77.21
+2.9%
$245.83
+218.4%
-37.4%$5.84B$475.60M-5.21791
EXEL
Exelixis
2.7481 of 5 stars
$18.21
+1.7%
$33.10
+81.8%
-16.4%$5.76B$987.54M35.71773Options Volume
ARNA
Arena Pharmaceuticals
1.7631 of 5 stars
$89.89
+0.1%
$96.67
+7.5%
+15.8%$5.53B$320K-9.28363
HALO
Halozyme Therapeutics
2.7414 of 5 stars
$33.53
+3.5%
$54.60
+62.8%
-29.9%$4.72B$267.59M12.02136
IONS
Ionis Pharmaceuticals
1.7931 of 5 stars
$31.48
+0.3%
$48.06
+52.7%
-49.1%$4.45B$729M-7.44757News Coverage
ALKS
Alkermes
2.1431 of 5 stars
$25.19
+1.5%
$28.71
+14.0%
+15.2%$4.07B$1.04B-43.432,245Analyst Revision
News Coverage
FOLD
Amicus Therapeutics
2.1148 of 5 stars
$9.50
+0.6%
$15.50
+63.2%
-54.7%$2.65B$260.89M-10.56483
BCRX
BioCryst Pharmaceuticals
2.2042 of 5 stars
$14.65
+2.7%
$19.82
+35.3%
+54.8%$2.62B$17.81M-11.54246
EBS
Emergent BioSolutions
2.6914 of 5 stars
$46.42
+0.5%
$76.20
+64.2%
-56.9%$2.50B$1.56B11.052,200Analyst Revision
MYGN
Myriad Genetics
1.5448 of 5 stars
$26.03
+3.2%
$30.00
+15.3%
+0.9%$2.08B$638.60M-29.922,700Gap Down
OPK
OPKO Health
1.9064 of 5 stars
$3.01
+7.3%
$6.33
+110.4%
-26.8%$2.05B$1.44B27.375,269Analyst Downgrade
Analyst Revision
News Coverage
LGND
Ligand Pharmaceuticals
2.3264 of 5 stars
$116.97
+0.6%
$223.75
+91.3%
-17.5%$1.95B$186.42M29.322,018News Coverage
IRWD
Ironwood Pharmaceuticals
2.2831 of 5 stars
$11.14
+0.5%
$14.50
+30.2%
+8.3%$1.82B$389.52M3.43232
CCXI
ChemoCentryx
2.1331 of 5 stars
$25.34
+1.1%
$75.00
+196.0%
-60.2%$1.77B$64.89M-14.56133Gap Down
DVAX
Dynavax Technologies
2.5881 of 5 stars
$12.60
+0.0%
$23.50
+86.5%
+141.4%$1.51B$46.55M-36.00245
CLDX
Celldex Therapeutics
2.2 of 5 stars
$29.40
+1.9%
$59.00
+100.7%
+62.1%$1.37B$7.42M-16.70124
CDXS
Codexis
2.0798 of 5 stars
$19.37
+6.0%
$32.80
+69.3%
-20.9%$1.26B$69.06M-80.70181News Coverage
Gap Down
IMGN
ImmunoGen
1.8931 of 5 stars
$5.40
+0.9%
$9.50
+75.9%
-26.2%$1.09B$132.30M-15.8879Gap Down
MDGL
Madrigal Pharmaceuticals
2.4514 of 5 stars
$62.83
+0.3%
$177.57
+182.6%
-46.1%$1.07BN/A-4.2942
INVA
Innoviva
1.7165 of 5 stars
$15.39
+3.8%
N/A+29.5%$1.07B$336.79M4.935
MNKD
MannKind
1.6498 of 5 stars
$3.68
+0.8%
$6.30
+71.2%
+4.8%$924.62M$65.14M-11.50241Gap Down
VNDA
Vanda Pharmaceuticals
2.4814 of 5 stars
$14.65
+0.6%
$20.00
+36.5%
+3.8%$816.18M$248.17M24.02292News Coverage
AGEN
Agenus
1.9931 of 5 stars
$2.68
+0.4%
$11.50
+329.1%
-21.8%$688.31M$88.17M-22.33359Gap Down
LXRX
Lexicon Pharmaceuticals
1.9714 of 5 stars
$3.14
+0.3%
$11.67
+271.5%
-63.2%$467.53M$24M-6.5478
ICPT
Intercept Pharmaceuticals
2.425 of 5 stars
$15.38
+1.5%
$30.21
+96.5%
-47.0%$454.43M$312.69M-4.75498Gap Down
RIGL
Rigel Pharmaceuticals
1.9931 of 5 stars
$2.43
+0.4%
$9.50
+290.9%
-35.5%$415.55M$108.62M-27.00169Gap Down
GERN
Geron
1.7998 of 5 stars
$1.10
+0.9%
$5.50
+400.0%
-35.8%$354.14M$250K-3.3354
VSTM
Verastem
2.2314 of 5 stars
$1.67
+7.8%
$6.33
+279.2%
-30.0%$304.25M$88.52M-3.8049Gap Down
CRIS
Curis
1.9398 of 5 stars
$3.22
+1.6%
$19.80
+514.9%
-70.2%$294.98M$10.84M-7.0028
CLVS
Clovis Oncology
2.0148 of 5 stars
$2.09
+1.4%
$6.88
+228.9%
-68.3%$271.66M$164.52M-0.74N/AGap Down
SABS
SAB Biotherapeutics
2.0333 of 5 stars
$5.96
+2.2%
$20.33
+241.2%
N/A$259.11MN/A0.005News Coverage
Positive News
Gap Down
XOMA
XOMA
1.7131 of 5 stars
$20.93
+1.1%
$49.00
+134.1%
-47.4%$236.74M$29.39M-104.6510
FBIO
Fortress Biotech
2.0914 of 5 stars
$2.26
+4.0%
$12.80
+466.4%
-38.7%$225.16M$45.60M-4.81111
ZIOP
ZIOPHARM Oncology
2.1031 of 5 stars
$0.87
+5.2%
$3.50
+300.7%
-74.7%$188.78MN/A-2.03105
MTEM
Molecular Templates
2.5814 of 5 stars
$3.17
+2.8%
$13.20
+316.4%
-72.9%$178.49M$18.84M-1.67239Gap Down
SPPI
Spectrum Pharmaceuticals
2.2848 of 5 stars
$0.99
+1.5%
$5.00
+405.3%
-75.6%$162.23MN/A-0.92176Positive News
BOLT
Bolt Biotherapeutics
2.3064 of 5 stars
$3.98
+2.5%
$39.80
+900.0%
N/A$148.39M$230K-0.2365
This page was last updated on 1/25/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.